Where MS Genetics and Vitamin D Converge on One Enzyme Step
Most accounts of multiple sclerosis (MS) risk present a list: vitamin D status, latitude, smoking, Epstein-Barr virus, HLA, and a few dozen variants of small effect. Grigorian and colleagues argue for something structurally different. In their account these factors converge on a single biochemical step, Golgi N-glycan branching, and defective branching then produces T cell hyperactivity, loss of self-tolerance, and neurodegeneration. The claim is that genetic variants in IL7RA, IL2RA, MGAT1 and CTLA-4 and environmental factors including vitamin D₃ and nutrient supply are not separate risks that add up, but inputs to one pathway that interact. Two things frame how to read it. The review comes from the laboratory that generated most of the evidence in it, and it was published in April 2012.
Why This Step Is Where Environment Meets Genome
The mechanism rests on a substrate shortage, and the numbers are the argument. Branching is carried out sequentially by Golgi enzymes encoded by Mgat1, Mgat2, Mgat4 and Mgat5, all drawing on UDP-GlcNAc produced by the hexosamine pathway. The Michaelis constant of Mgat4 for UDP-GlcNAc is roughly 5 mM and that of Mgat5 roughly 11 mM, while Golgi UDP-GlcNAc concentration sits at about 1.5 mM. These enzymes work far below saturation, so small shifts in substrate supply translate into large shifts in branching. That mismatch is the mechanical basis for everything downstream, and it explains why a structural feature of proteins should be sensitive to diet and metabolic state at all. On the cell membrane, galectins form a lattice whose binding avidity scales with two things: how many N-glycans a protein carries, which the genome fixes, and how heavily they branch, which the environment moves. Growth-promoting receptors carry more than five N-glycans and growth-inhibitory receptors four or fewer, so one metabolic change pushes stimulatory and inhibitory signalling in opposite directions.
The Same Variant Can Raise or Lower Risk
The sharpest claim in the review is that a risk allele's direction depends on what else is present. The MGAT1 IV₂V₃₃ haplotype raises Mgat1 messenger RNA and enzyme activity roughly two to three fold. Under basal UDP-GlcNAc that reduces branching, because Mgat1 outcompetes the downstream Mgat4 and Mgat5 for limited substrate. Given more UDP-GlcNAc or more Mgat5, the same haplotype enhances branching instead. The genetic interactions follow that logic rather than being fitted to it afterward. The haplotype raises MS risk when fewer than four copies of the IL2RA*T and IL7RA*C risk alleles are present, and shows no association at four copies. It associates with MS in CTLA-4 Ala17 carriers, who carry one N-glycan at that site, but not in CTLA-4 Thr17 homozygotes, who carry two. With six alleles of CTLA-4 Thr17, IL2RA*T and IL7RA*C together, the effect turns marginally protective.
What That Implies About Point-Association Studies
The methodological point is stated plainly and travels well beyond MS. These interactions appear despite CTLA-4 Thr17Ala showing no point association with MS and only marginal effects alone. A study testing variants one at a time would find none of it. The authors set this against the missing heritability problem, noting that identified MS variants explain only about 20% of the genetic variance known to exist, and against a cautionary example from sickle cell anaemia, where a GWAS returned 179 non-causal polymorphisms at genome-wide significance across a 2.5 Mb region despite the single causal variant having been established for years. Their conclusion is that studies examining only point association are unlikely to define heritability in diseases of this kind, and that molecular work in mice is needed to choose which interactions are worth testing in humans rather than searching blindly.
The Vitamin D Result, and the Experiment That Makes It Causal
1,25-dihydroxyvitamin D₃ increases branching in activated T cells and suppresses their growth. Lowering dietary vitamin D₃ in mice decreased branching, and injecting the active form increased it. The experiment that turns correlation into mechanism is a blocking one: 1,25(OH)₂D₃ inhibited myelin basic protein-induced experimental autoimmune encephalomyelitis in the absence of swainsonine, an inhibitor of N-glycan branching, but not in its presence. That puts branching on the causal path between vitamin D and disease rather than beside it. The gene-environment interaction runs through MGAT1 again, since 1,25(OH)₂D₃ raises MGAT1 messenger RNA, acting like the risk haplotype and opposite to IL2RA*T and IL7RA*C. In T cells carrying two or more of those risk alleles, vitamin D₃ enhanced branching; in cells homozygous for both protective alleles, where Mgat1 was never suppressed, it did not. Since only about 0.5% of Caucasians carry that protective combination, vitamin D₃ deficiency on this account would reduce branching in nearly everyone.
A Therapeutic Prediction With an Unusual Amount of Detail
N-acetylglucosamine is the candidate, and the reasoning for preferring it over glucosamine is the kind of detail that makes a hypothesis testable. Glucosamine can be shunted into glycolysis and ATP production, and when titrated in culture it first raises branching and then lowers it. N-acetylglucosamine cannot enter glycolysis, is not metabolised, and only enhances branching. In mice it limits T cell receptor signalling, raises retention of CTLA-4 on the membrane, inhibits T helper 1 and T helper 17 responses, and suppresses both experimental autoimmune encephalomyelitis and autoimmune diabetes, including when given after disease onset. The human evidence cited is a pilot study in paediatric treatment-resistant inflammatory bowel disease: 8 of 12 children entered clinical remission with histological improvement, three relapsed within roughly a month of stopping, and improved again when it was restarted. On that basis the review concludes that a human clinical trial in MS is warranted.
What the Review Concedes, and What a 2012 Argument Cannot Answer
The stated gap is specific. While the effects on T cells are defined in both mice and humans, the authors write that further work is required to determine whether these genetic and environmental factors also directly alter innate immune activity and neurodegeneration in human cells through defective N-glycosylation. The neurodegeneration half of the thesis therefore rests on mouse data: neurons with targeted Mgat1 deficiency undergo apoptosis in vivo, and PL/J mice with Mgat5 deficiency develop spontaneous late-onset disease with inflammatory demyelination and neuron loss. Two further things belong in a reader's assessment. This is a review by the laboratory whose work it reviews, which is ordinary for an invited article but does shape which results receive weight, and one supporting claim is cited as unpublished data. And the paper appeared in April 2012, which means its closing call for a trial of N-acetylglucosamine in MS has had fourteen years to be answered. Whether it was, and with what outcome, is the question this review cannot settle and the first thing to establish before treating its conclusion as current.
Disclaimer: This blog post is based on the cited review article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
Reference:
Grigorian, A., Mkhikian, H., Li, C. F., Newton, B. L., Zhou, R. W., & Demetriou, M. (2012). Pathogenesis of multiple sclerosis via environmental and genetic dysregulation of N-glycosylation. Seminars in Immunopathology, 34(3), 415–424. https://doi.org/10.1007/s00281-012-0307-y
